SAKK 06/19
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
- NCT04630730 ↗
- Active, not recruiting
- Swiss Cancer Institute
- Deep
We haven't built an HCP commentary report on SAKK 06/19 (VPM1002BC plus atezolizumab plus cisplatin plus gemcitabine in muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 26 newest of 27 indexed sources (Jan 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether findings merit validation in larger comparative studies
- Whether the approach can support bladder preservation and reduce cystectomy need
- Whether rBCG adds benefit to perioperative chemo-immunotherapy
- How the regimen fits with EV-P, including possible combination strategies
Also discussed: toxicity, patient selection.
Indexed commentary on SAKK 06/19 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 26 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC); Atezolizumab; Cisplatin; Gemcitabine
- Arms
- Recombinant intravesical BCG · Experimental
- Enrollment
- 46 (estimated)
- Primary outcomes
- Pathological complete remission (pCR)
- Sponsor
- Swiss Cancer Institute
- Start
- Jun 24, 2022
- Primary completion
- Apr 26, 2026
- Results posted
- No
- Registry record
- NCT04630730 · updated Oct 23, 2026
Publications
linked from the registry- Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R. Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). BMJ Open. 2023 Jun 7;13(6):e067634. doi: 10.1136/bmjopen-2022-067634. PubMed 37286312